Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Open accessThe DOI matches its Crossref record; 486 of the 486 references it cites were found in a registry or an index.
Abstract
Cancers are highly complex diseases that are characterized by not only the overgrowth of malignant cells but also an altered immune response. The inhibition and reprogramming of the immune system play critical roles in tumor initiation and progression. Immunotherapy aims to reactivate antitumor immune cells and overcome the immune escape mechanisms of tumors. Represented by immune checkpoint blockade and adoptive cell transfer, tumor immunotherapy has seen tremendous success in the clinic, with the capability to induce long-term regression of some tumors that are refractory to all other treatments. Among them, immune checkpoint blocking therapy, represented by PD-1/PD-L1 inhibitors (nivolumab) and CTLA-4 inhibitors (ipilimumab), has shown encouraging therapeutic effects in the treatment of various malignant tumors, such as non-small cell lung cancer (NSCLC) and melanoma. In addition, with the advent of CAR-T, CAR-M and other novel immunotherapy methods, immunotherapy has entered a new era. At present, evidence indicates that the combination of multiple immunotherapy methods may be one way to improve the therapeutic effect. However, the overall clinical response rate of tumor immunotherapy still needs improvement, which warrants the development of novel therapeutic designs as well as the discovery of biomarkers that can guide the prescription of these agents. Learning from the past success and failure of both clinical and basic research is critical for the rational design of studies in the future. In this article, we describe the efforts to manipulate the immune system against cancer and discuss different targets and cell types that can be exploited to promote the antitumor immune response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 201–400 of 486
Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia
He, X., Feng, Z., Ma, J., Ling, S., Cao, Y., Gurung, B., Wu, Y., Katona, B. W., O’Dwyer, K. P., Siegel, D. L., et al. (2020) · Blood · doi:10.1182/blood.2019002779 · Cited by 208
Gong, J., Wang, C., Lee, P. P., Chu, P., & Fakih, M. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0016 · Cited by 207
Regulation of the T Cell Response by CD39
Takenaka, M. C., Robson, S., & Quintana, F. J. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.009 · Cited by 207
Oncolytic Virus Therapy for Glioblastoma Multiforme: Concepts and Candidates
Wollmann, G., Ozduman, K., & van den Pol, A. N. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824671c9 · Cited by 205
Role of PD-1 in Immunity and Diseases
Chamoto, K., Al-Habsi, M., & Honjo, T. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_67 · Cited by 200
PD-1 Blockade in Advanced Adrenocortical Carcinoma
Raj, N., Zheng, Y., Kelly, V., Katz, S. S., Chou, J., Do, R. K. G., Capanu, M., Zamarin, D., Saltz, L. B., Ariyan, C. E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01586 · Cited by 200
Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
Oliveira, A. F., Bretes, L., & Furtado, I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00396 · Cited by 198
Martin, P. J., Ledbetter, J. A., Morishita, Y., June, C. H., Beatty, P. G., & Hansen, J. A. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.9.3282 · Cited by 196
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells
Lichtenstein, D. A., Schischlik, F., Shao, L., Steinberg, S. M., Yates, B., Wang, H.-W., Wang, Y., Inglefield, J., Dulau-Florea, A., Ceppi, F., et al. (2021) · Blood · doi:10.1182/blood.2021011898 · Cited by 196
Target selection for CAR-T therapy
Wei, J., Han, X., Bo, J., & Han, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0758-x · Cited by 195
Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy
Yang, Y., & Lundqvist, A. (2020) · Cancers · doi:10.3390/cancers12123586 · Cited by 189
CAR T cell therapy: inroads to response and resistance
Brown, C. E., & Mackall, C. L. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0119-y · Cited by 187
Ramesh, A., Kumar, S., Nandi, D., & Kulkarni, A. (2019) · Advanced Materials · doi:10.1002/adma.201904364 · Cited by 187
Powell, S. F., Rodríguez-Abreu, D., Langer, C. J., Tafreshi, A., Paz-Ares, L., Kopp, H.-G., Rodríguez-Cid, J., Kowalski, D. M., Cheng, Y., Kurata, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.020 · Cited by 186
CD39 Regulation and Functions in T Cells
Timperi, E., & Barnaba, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158068 · Cited by 186
Microglial immune checkpoint mechanisms
Deczkowska, A., Amit, I., & Schwartz, M. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0145-x · Cited by 185
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
Kim, C. G., Kim, C., Yoon, S. E., Kim, K. H., Choi, S. J., Kang, B., Kim, H. R., Park, S.-H., Shin, E.-C., Kim, Y.-Y., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.010 · Cited by 185
Wang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1243 · Cited by 183
Self-citationStenger, D., Stief, T. A., Kaeuferle, T., Willier, S., Rataj, F., Schober, K., Vick, B., Lotfi, R., Wagner, B., Grünewald, T. G. P., et al. (2020) · Blood · doi:10.1182/blood.2020005185 · Cited by 182
Huang, Y., Guan, Z., Dai, X., Shen, Y., Wei, Q., Ren, L., Jiang, J., Xiao, Z., Jiang, Y., Liu, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24564-0 · Cited by 182
Benson, D. M., Cohen, A. D., Jagannath, S., Munshi, N. C., Spitzer, G., Hofmeister, C. C., Efebera, Y. A., Andre, P., Zerbib, R., & Caligiuri, M. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0304 · Cited by 180
Immunotherapy of Cancer with 4-1BB
Vinay, D. S., & Kwon, B. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0677 · Cited by 180
van de Ven, K., & Borst, J. (2015) · Immunotherapy · doi:10.2217/imt.15.32 · Cited by 177
The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer
Yasinska, I. M., Sakhnevych, S. S., Pavlova, L., Teo Hansen Selnø, A., Teuscher Abeleira, A. M., Benlaouer, O., Gonçalves Silva, I., Mosimann, M., Varani, L., Bardelli, M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01594 · Cited by 177
Yamauchi, T., Hoki, T., Oba, T., Jain, V., Chen, H., Attwood, K., Battaglia, S., George, S., Chatta, G., Puzanov, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21619-0 · Cited by 176
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
Zhang, M., Wen, B., Antón, O. M., Yao, Z., Dubois, S. P., Ju, W., Sato, N., DiLillo, D. J., Bamford, R. N., Ravetch, J. V., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811615115 · Cited by 172
Sandler, R. D., Tattersall, R. S., Schoemans, H., Greco, R., Badoglio, M., Labopin, M., Alexander, T., Kirgizov, K., Rovira, M., Saif, M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00524 · Cited by 172
Awad, M. M., Gadgeel, S. M., Borghaei, H., Patnaik, A., Yang, J. C.-H., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Altan, M., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.015 · Cited by 172
Deng, S., Li, X., Liu, S., Chen, J., Li, M., Chew, S. Y., Leong, K. W., & Cheng, D. (2020) · Science Advances · doi:10.1126/sciadv.abb4005 · Cited by 169
Counteracting CAR T cell dysfunction
Poorebrahim, M., Melief, J., Pico de Coaña, Y., L. Wickström, S., Cid-Arregui, A., & Kiessling, R. (2021) · Oncogene · doi:10.1038/s41388-020-01501-x · Cited by 168
Tu, L., Guan, R., Yang, H., Zhou, Y., Hong, W., Ma, L., Zhao, G., & Yu, M. (2020) · International Journal of Cancer · doi:10.1002/ijc.32785 · Cited by 167
CTLA-4 Regulates Tolerance Induction and T Cell Differentiation In Vivo
Walunas, T. L., & Bluestone, J. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.8.3855 · Cited by 166
Carlsten, M., Korde, N., Kotecha, R., Reger, R., Bor, S., Kazandjian, D., Landgren, O., & Childs, R. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1108 · Cited by 166
Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
Guo, Y., Lei, K., & Tang, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01499 · Cited by 166
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
Etxeberría, I., Glez‐Vaz, J., Teijeira, Á., & Melero, I. (2019) · ESMO Open · doi:10.1136/esmoopen-2020-000733 · Cited by 166
New emerging targets in cancer immunotherapy: CD27 (TNFRSF7)
Starzer, A. M., & Berghoff, A. S. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000629 · Cited by 165
Minireview: Role Of Orphan Nuclear Receptors in Cancer and Potential as Drug Targets
Safe, S. H., Jin, U.-H., Hedrick, E., Reeder, A., & Lee, S. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1291 · Cited by 164
Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma
Xiao, Z., Chung, H., Banan, B., Manning, P. T., Ott, K. C., Lin, S., Capoccia, B. J., Subramanian, V., Hiebsch, R. R., Upadhya, G. A., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.036 · Cited by 164
CAR‐NK cell in cancer immunotherapy; A promising frontier
Marofi, F., Abdul‐Rasheed, O. F., Rahman, H. S., Budi, H. S., Jalil, A. T., Yumashev, A. V., Hassanzadeh, A., Yazdanifar, M., Motavalli, R., Chartrand, M. S., et al. (2021) · Cancer Science · doi:10.1111/cas.14993 · Cited by 164
Davis, R. J., Van Waes, C., & Allen, C. T. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.002 · Cited by 163
Schöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003776 · Cited by 163
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
García-Díaz, Á., Shin, D. S., Moreno, B. H., Saco, J. D., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.113 · Cited by 162
Harding, J. J., Moreno, V., Bang, Y.-J., Hong, M. H., Patnaik, A., Trigo, J., Szpurka, A. M., Yamamoto, N., Doi, T., Fu, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4405 · Cited by 161 · cited 1×
“Tim-3, also known as HAVCR2, was later found to also be expressed on some innate immune cells, including dendritic cells, NK cells, monocytes, and macrophages.(163) In IA/ IB studies, the Tim-3 blocking antibody LY3321367 was well tolerated as a single agent or in combination with an anti-PD-L1 antibody.”
BackgroundAllogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
Bedoya, D. M., Dutoit, V., & Migliorini, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640082 · Cited by 161
The Aryl Hydrocarbon Receptor and Tumor Immunity
Xue, P., Fu, J., & Zhou, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00286 · Cited by 160
Cytokine production by human neutrophils: Revisiting the “dark side of the moon”
Tamassia, N., Bianchetto‐Aguilera, F., Arruda‐Silva, F., Gardiman, E., Gasperini, S., Calzetti, F., & Cassatella, M. A. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12952 · Cited by 160
A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies
Razeghian, E., Nasution, M. K. M., Rahman, H. S., Gardanova, Z. R., Abdelbasset, W. K., Surendar, A., Bokov, D. O., Suksatan, W., Nakhaei, P., Shariatzadeh, S., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02510-7 · Cited by 160
New directions for emerging therapies in acute myeloid leukemia: the next chapter
Daver, N., Wei, A. H., Pollyea, D. A., Fathi, A. T., Vyas, P., & DiNardo, C. D. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00376-1 · Cited by 159
Wu, L., Deng, W.-W., Huang, C.-F., Bu, L.-L., Yu, G.-T., Mao, L., Zhang, W.-F., Liu, B., & Sun, Z.-J. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1968-0 · Cited by 158
IDO1: An important immunotherapy target in cancer treatment
Li, F., Zhang, R., Li, S., & Liu, J. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.03.024 · Cited by 158
Böger, C., Behrens, H.-M., Krüger, S., & Röcken, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1293215 · Cited by 156
T cell antigen discovery via signaling and antigen-presenting bifunctional receptors
Joglekar, A. V., Leonard, M. T., Jeppson, J. D., Swift, M., Li, G., Wong, S., Peng, S., Zaretsky, J. M., Heath, J. R., Ribas, A., et al. (2019) · Nature Methods · doi:10.1038/s41592-018-0304-8 · Cited by 155
Lakhani, N. J., Chow, L. Q. M., Gainor, J. F., LoRusso, P. M., Lee, K.-W., Chung, H. C., Lee, J., Bang, Y.-J., Hodi, F. S., Kim, W. S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00584-2 · Cited by 153
Wolchok, J. D. (2015) · Cell · doi:10.1016/j.cell.2015.07.045 · Cited by 149
Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
Luen, S. J., Savas, P. S., Fox, S. B., Salgado, R., & Loi, S. (2017) · Pathology · doi:10.1016/j.pathol.2016.10.010 · Cited by 149
Colon Cancer Cell Secretes EGF to Promote M2 Polarization of TAM Through EGFR/PI3K/AKT/mTOR Pathway
Lian, G., Chen, S., Ouyang, M., Li, F., Chen, L., & Yang, J. (2019) · Technology in Cancer Research & Treatment · doi:10.1177/1533033819849068 · Cited by 144
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
Qian, W., Zhao, M., Wang, R., & Li, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01161-8 · Cited by 144
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Khasraw, M., Reardon, D. A., Weller, M., & Sampson, J. H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1135 · Cited by 143
Wong, J. S. L., Kwok, G. G. W., Tang, V., Li, B. C. W., Leung, R., Chiu, J., Ma, K. W., She, W. H., Tsang, J., Lo, C. M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001945 · Cited by 142 · cited 1×
“Different from nivolumab, the prescription of pembrolizumab requires confirmed PD-L1 overexpression on tumors.(113,114) Nivolumab and pembrolizumab (coreda) were later approved as single agents for the second-line treatment of NSCLC (non-small cell lung cancer).”
BackgroundWang, X., Naranjo, A., Brown, C. E., Bautista, C., Wong, C. W., Chang, W.-C., Aguilar, B., Ostberg, J. R., Riddell, S. R., Forman, S. J., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318270dec7 · Cited by 142
On the mechanism of anti-CD39 immune checkpoint therapy
Allard, D., Allard, B., & Stagg, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000186 · Cited by 142
Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy
Jiang, H., Liu, L., Guo, T., Wu, Y., Ai, L., Deng, J., Dong, J. W., Mei, H., & Hu, Y. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03685-z · Cited by 141
Comparative analysis of assays to measure CAR T cell-mediated cytotoxicity
Kiesgen, S., Messinger, J. C., Chintala, N. K., Tano, Z., & Adusumilli, P. S. (2021) · Nature Protocols · doi:10.1038/s41596-020-00467-0 · Cited by 138 · cited 1×
“Autologous T cells are inconsistent in their quality and quantity, especially in patients who have been heavily pretreated with radiation and chemotherapy.(337) The development of allogeneic “universal” CAR-T products aims to address these challenges.”
BackgroundThe biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Wang, X., Wang, F., Zhong, M., Yarden, Y., & Fu, L. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01200-x · Cited by 137
Blocking IDO activity to enhance anti-tumor immunity
Munn, D. H. (2012) · Frontiers in Bioscience · doi:10.2741/e414 · Cited by 136
Burris, H. A., Infante, J. R., Ansell, S. M., Nemunaitis, J. J., Weiss, G. R., Villalobos, V. M., Sikic, B. I., Taylor, M. H., Northfelt, D. W., Carson, W. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1508 · Cited by 135
Cassell, D. J., & Schwartz, R. H. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.5.1829 · Cited by 133
CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
Mittal, D., Lepletier, A., Madore, J., Aguilera, A. R., Stannard, K. A., Blake, S. J., Whitehall, V., Liu, C., Bettington, M. L., Takeda, K., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0637 · Cited by 133
Shi, L., Sheng, J., Chen, G., Zhu, P., Shi, C., Li, B., Park, C., Wang, J., Zhang, B., Liu, Z., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000973 · Cited by 133
Neoantigen quality, not quantity
McGranahan, N., & Swanton, C. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7918 · Cited by 132
Sadelain, M. (2017) · Cell · doi:10.1016/j.cell.2017.12.002 · Cited by 131
Fucà, G., Cohen, R., Lonardi, S., Shitara, K., Elez, M. E., Fakih, M., Chao, J., Klempner, S. J., Emmett, M., Jayachandran, P., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004001 · Cited by 129 · cited 1×
“In May 2017, pembrolizumab was approved for solid tumor patients with MSI-H or dMMR who have progressed after previous treatment and have no satisfactory alternative treatment.(386,396,398) In 2017 and 2018, the FDA successively approved the treatment of metastatic colorectal cancer patients with MSI-H or dMMR after t…”
The role of exhaustion in CAR T cell therapy
Delgoffe, G. M., Xu, C., Mackall, C. L., Green, M. R., Gottschalk, S. M., Speiser, D. E., Zehn, D., & Beavis, P. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.012 · Cited by 129
Klümper, N., Ralser, D. J., Bawden, E., Landsberg, J., Zarbl, R., Kristiansen, G., Toma, M. I., Ritter, M., Hölzel, M., Ellinger, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000552 · Cited by 124
CAR-T cells and BiTEs in solid tumors: challenges and perspectives
Edeline, J., Houot, R., Marabelle, A., & Alcantara, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01067-5 · Cited by 123
Bian, Z., Shi, L., Kidder, K., Zen, K., Garnett‐Benson, C., & Liu, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-23442-z · Cited by 122
T-cell agonists in cancer immunotherapy
Choi, Y., Shi, Y., Haymaker, C. L., Naing, A., Ciliberto, G., & Hajjar, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000966 · Cited by 119
CD4 CTL: Living up to the challenge
Cheroutre, H., & Husain, M. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.022 · Cited by 119
Oncolytic virus therapy for cancer: the first wave of translational clinical trials
Patel, M. R., & Kratzke, R. A. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.010 · Cited by 119
Cascone, T., Weissferdt, A., Godoy, M. C. B., William, W. N., Leung, C. H., Lin, H. Y., Basu, S., Yadav, S. S., Pataer, A., Mitchell, K. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25188-0 · Cited by 118
The Application of Nanobody in CAR-T Therapy
Bao, C., Gao, Q., Li, L., Han, L., Zhang, B., Ding, Y., Song, Z., Zhang, R., Zhang, J., & Wu, X.-H. (2021) · Biomolecules · doi:10.3390/biom11020238 · Cited by 117
Self-citationMacrophage, the potential key mediator in CAR-T related CRS
Hao, Z., Li, R., Li, M., Han, Z., & Hong, Z. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00171-5 · Cited by 116
Coming of Age: CD96 Emerges as Modulator of Immune Responses
Georgiev, H., Ravens, I., Papadogianni, G., & Bernhardt, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01072 · Cited by 115
Blocking IDO activity to enhance anti-tumor immunity
Munn, D. (2012) · Frontiers in Bioscience · doi:10.2741/414 · Cited by 114
Buchan, S. L., Fallatah, M., Thirdborough, S. M., Taraban, V. Y., Rogel, A., Thomas, L. J., Penfold, C. A., He, L.-Z., Curran, M. A., Keler, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3057 · Cited by 114
Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis
Yang, H., Shao, R., Huang, H., Wang, X., Rong, Z., & Lin, Y. (2019) · Cancer Medicine · doi:10.1002/cam4.2332 · Cited by 113
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
Khawanky, N. E., Hughes, A., Yu, W., Myburgh, R., Matschulla, T., Taromi, S., Aumann, K., Clarson, J., Vinnakota, J. M., Shoumariyeh, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26683-0 · Cited by 112
Mollanoori, H., Shahraki, H., Rahmati, Y., & Teimourian, S. (2018) · Human Immunology · doi:10.1016/j.humimm.2018.09.007 · Cited by 109
Inflammatory myopathy associated with PD-1 inhibitors
Seki, M., Uruha, A., Ohnuki, Y., Kamada, S., Noda, T., Onda, A., Ohira, M., Isami, A., Hiramatsu, S., Hibino, M., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.03.005 · Cited by 108
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., Páyer, Á. R., González-García, E., López‐Soto, A., & Gonzalez, S. R. (2021) · Cancers · doi:10.3390/cancers13092112 · Cited by 108
CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer
de Lara, P. T., Castañón, H., Vermeer, M., Núñez, N. G., Siliņa, K., Sobottka, B., Urdinez, J., Cecconi, V., Yagita∥, H., Attar, F. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21045-2 · Cited by 107
Myers, G. D., Verneris, M. R., Goy, A. H., & Maziarz, R. T. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002056 · Cited by 106
Immune Checkpoint Inhibitors in Prostate Cancer
Venkatachalam, S., McFarland, T. R., Agarwal, N., & Swami, U. (2021) · Cancers · doi:10.3390/cancers13092187 · Cited by 106
CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer
Bengsch, F., Knoblock, D. M., Liu, A., McAllister, F., & Beatty, G. L. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2053-4 · Cited by 105
Deuss, F. A., Gully, B. S., Rossjohn, J., & Berry, R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.786483 · Cited by 104
Neurological updates: neurological complications of CAR-T therapy
Tallantyre, E. C., Evans, N. A., Parry-Jones, J., Morgan, M. P. G., Jones, C. H., & Ingram, W. A. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10237-3 · Cited by 104
Lynch Syndrome and MSI-H Cancers: From Mechanisms to “Off-The-Shelf” Cancer Vaccines
Roudko, V., Bozkus, C. C., Greenbaum, B. D., Lucas, A. L., Samstein, R. M., & Bhardwaj, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.757804 · Cited by 104
Myeloid Cell Origins, Differentiation, and Clinical Implications
Weiskopf, K., Schnorr, P. J., Pang, W. W., Chao, M. P., Chhabra, A., Seita, J., Feng, M., & Weissman, I. L. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0031-2016 · Cited by 103
Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
Pan, J., Deng, B., Ling, Z., Song, W., Xu, J., Duan, J., Wang, Z., Chang, A. H., Feng, X., & Tan, Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16176 · Cited by 101
The role of KIR and HLA interactions in pregnancy complications
Colucci, F. (2017) · Immunogenetics · doi:10.1007/s00251-017-1003-9 · Cited by 100
Eguizabal, C., Zenarruzabeitia, O., Monge, J., Santos, S., Vesga, M. A., Maruri, N., Arrieta, A., Riñón, M., Tamayo-Orbegozo, E., Amo, L., et al. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00439 · Cited by 99
Koh, J., Kim, Y., Lee, K. Y., Hur, J. Y., Kim, M. S., Kim, B., Cho, H. J., Lee, Y. C., Bae, Y. H., Ku, B. M., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048534 · Cited by 95
Giglio, A. D., Federico, A. D., Nuvola, G., Deiana, C., & Gelsomino, F. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01124-9 · Cited by 95
TAM Receptor Inhibition–Implications for Cancer and the Immune System
Aehnlich, P., Powell, R., Peeters, M. J. W., Rahbech, A., & Straten, P. T. (2021) · Cancers · doi:10.3390/cancers13061195 · Cited by 93
Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead
Soltantoyeh, T., Akbari, B., Karimi, A., Chalbatani, G. M., Ghahri-Saremi, N., Hadjati, J., Hamblin, M. R., & Mirzaei, H. R. (2021) · Cells · doi:10.3390/cells10061450 · Cited by 93
Passiglia, F., Galvano, A., Rizzo, S., Incorvaia, L., Listì, A., Bazan, V., & Russo, A. D. (2017) · International Journal of Cancer · doi:10.1002/ijc.31136 · Cited by 92
van de Loosdrecht, A. A., van Wetering, S., Santegoets, S. J. A. M., Singh, S., Eeltink, C., den Hartog, Y. M., Koppes, M., Kaspers, J., Ossenkoppele, G. J., Kruisbeek, A. M., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2198-9 · Cited by 92
Tinker, A. V., Hirte, H. W., Provencher, D. M., Butler, M. O., Ritter, H. D., Tu, D., Azim, H. A., Paralejas, P., Grenier, N., Hahn, S.-A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0298 · Cited by 92
Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment
Gao, X., Sui, H., Zhao, S., Gao, X., Su, Y., & Qu, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585214 · Cited by 91
Liu, C. J., Schaettler, M. O., Blaha, D. T., Bowman-Kirigin, J. A., Kobayashi, D. K., Livingstone, A. J., Bender, D. E., Miller, C. A., Kranz, D. M., Johanns, T. M., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa050 · Cited by 90
Tumor-associated macrophages: role in tumorigenesis and immunotherapy implications
Zhu, S., Luo, Z., Li, X., Han, X., Shi, S., & Zhang, T. (2020) · Journal of Cancer · doi:10.7150/jca.49692 · Cited by 86
Control of Metastases via Myeloid CD39 and NK Cell Effector Function
Yan, J., Li, X.-Y., Aguilera, A. R., Xiao, C., Jacoberger-Foissac, C., Nowlan, B., Robson, S. C., Beers, C., Moesta, A. K., Geetha, N., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0749 · Cited by 85
CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer
Azangou‐Khyavy, M., Ghasemi, M., Khanali, J., Boroomand-Saboor, M., Jamalkhah, M., Soleimani, M., & Kiani, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02062 · Cited by 85
Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer
Wang, Y., Wang, C., Qiu, J., Qu, X., Peng, J., Lu, C., Zhang, M., Zhang, M., Qi, X., Li, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003667 · Cited by 83
Klepsch, V., Hermann‐Kleiter, N., Do-Dinh, P., Jakic, B., Offermann, A., Efremova, M., Sopper, S., Rieder, D., Krogsdam, A., Gamerith, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04004-2 · Cited by 81
Nivolumab for the treatment of colorectal cancer
Smith, K. M., & Desai, J. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1480942 · Cited by 81
Xie, W., Medeiros, L. J., Li, S., Yin, C. C., Khoury, J. D., & Xu, J. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00589-y · Cited by 81
Xie, G., Ivica, N. A., Jia, B., Li, Y., Dong, H., Liang, Y., Brown, D. R., Romee, R., & Chen, J. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00625-5 · Cited by 81
Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer
Morgensztern, D., & Herbst, R. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2998 · Cited by 80
NK cell therapy for hematologic malignancies
Mehta, R., Randolph, B., Daher, M., & Rezvani, K. (2018) · International journal of hematology · doi:10.1007/s12185-018-2407-5 · Cited by 80
Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives
Taguchi, S., Fukuhara, H., & Todo, T. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy170 · Cited by 80
Baird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., Oak, J. S., Younes, S. F., Ozawa, M. G., Yang, E., et al. (2021) · Blood · doi:10.1182/blood.2020009432 · Cited by 79
Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study
Hashemi, S. M. S., Fransen, M. F., Niemeijer, A.-L. N., Taleb, N., Houda, I., Veltman, J. D., Becker‐Commissaris, A., Daniels, J. M. A., Crombag, L. M. M. J., Radonic, T., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.01.013 · Cited by 78
Shao, M., Teng, X., Guo, X., Zhang, H., Huang, Y., Cui, J., Si, X., Ding, L., Wang, X., Li, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202103508 · Cited by 76
Adoptive Cell Therapy for Metastatic Melanoma
Merhavi-Shoham, E., Itzhaki, O., Markel, G., Schachter, J., & Besser, M. J. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000240 · Cited by 75
Leem, G., Park, J., Jeon, M., Kim, E.-S., Kim, S. W., Lee, Y. J., Choi, S. J., Choi, B., Park, S., Jung, I., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001650 · Cited by 73
Ansell, S. M., Flinn, I. W., Taylor, M. H., Sikic, B. I., Brody, J., Nemunaitis, J. J., Feldman, A. L., Hawthorne, T. R., Rawls, T., Keler, T., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001079 · Cited by 72
Chimeric Antigen Receptor beyond CAR-T Cells
Qin, V. M., D’Souza, C., Neeson, P. J., & Zhu, J. J. (2021) · Cancers · doi:10.3390/cancers13030404 · Cited by 72
Lam, T., Tsang, K. C., Choi, C., Lee, V. H.-F., Lam, K. O., Chiang, C., So, T. H., Chan, W., Nyaw, S. F., Lim, F., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.07.004 · Cited by 72
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Kim, T. W., Burris, H. A., Miguel, M. J. D., Pishvaian, M. J., Bang, Y., Gordon, M. S., Awada, A. H., Camidge, D. R., Hodi, F. S., McArthur, G. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4020 · Cited by 72
The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance
Hermann‐Kleiter, N., Klepsch, V., Wallner, S., Siegmund, K., Klepsch, S., Tuzlak, S., Villunger, A., Kaminski, S., Pfeifhofer‐Obermair, C., Gruber, T., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.035 · Cited by 71
Genetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy
Moyes, K. W., Lieberman, N. A. P., Kreuser, S. A., Chinn, H. K., Winter, C., Deutsch, G. H., Hoglund, V. J., Watson, R., & Crane, C. A. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.060 · Cited by 71
NK-DC Crosstalk in Immunity to Microbial Infection
Thomas, R., & Yang, X. (2016) · Journal of Immunology Research · doi:10.1155/2016/6374379 · Cited by 71
BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
Demerle, C., Gorvel, L., & Olive, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682007 · Cited by 71
Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
Ramakrishna, V., Sundarapandiyan, K., Zhao, B., Bylesjö, M., Marsh, H. C., & Keler, T. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0080-2 · Cited by 70
T-cell immunometabolism against cancer
Jiang, S., & Yan, W. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.09.003 · Cited by 69
Lobo, J., Rodrigues, Â., Guimarães, R., Cantante, M., Lopes, P., Maurício, J., Oliveira, J., Jerónimo, C., & Henrique, R. (2019) · Cancers · doi:10.3390/cancers11101535 · Cited by 69
Hofer, F., Sario, G. D., Musiu, C., Sartoris, S., Sanctis, F. D., & Ugel, S. (2021) · Cells · doi:10.3390/cells10102700 · Cited by 69
CD27 expression on Treg cells limits immune responses against tumors
Muth, S., Klaric, A., Radsak, M. P., Schild, H., & Probst, H. C. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02116-9 · Cited by 68
How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?
Liu, Y., & Zheng, P. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.10.009 · Cited by 67
Camelliti, S., Noci, V. L., Bianchi, F., Moscheni, C., Arnaboldi, F., Gagliano, N., Balsari, A., Garassino, M. C., Tagliabue, E., Sfondrini, L., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01721-9 · Cited by 67
Weber, S., van der Leest, P., Donker, H. C., Schlange, T., Timens, W., Tamminga, M., Hasenleithner, S. O., Graf, R., Moser, T., Spiegl, B., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00182 · Cited by 67
Xue, G., Zheng, N., Fang, J., Jin, G., Li, X., Dotti, G., Yi, Q., & Lu, Y. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.011 · Cited by 66
Li, X., Xu, Z., Cui, G., Li, Y., & Zhang, X. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s232234 · Cited by 63
Chen, H., Wei, F., Yin, M., Zhao, Q., Liu, Z., Yu, B., & Huang, Z. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02838-8 · Cited by 63
Kroemer, G., & Zitvogel, L. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201979 · Cited by 62
Lin, S., Yang, C., Liao, B.-C., Ho, C., Liao, W., Chen, K., Tsai, T.-H., Hsu, C., Hsu, W., Su, K., et al. (2018) · Journal of Cancer · doi:10.7150/jca.24985 · Cited by 61
Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra
Jatiani, S., Aleman, A., Madduri, D., Chari, A., Cho, H. J., Richard, S., Richter, J. R., Brody, J., Jagannath, S., & Parekh, S. S. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.04.020 · Cited by 61
Lee, J., Kang, T. H., Yoo, W., Choi, H., Jo, S., Kong, K., Lee, S., Kim, S.-U., Kim, J.-S., Cho, D., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0317 · Cited by 60
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
Kashyap, A. S., Thelemann, T., Klar, R., Kallert, S. M., Festag, J., Buchi, M., Hinterwimmer, L., Schell, M., Michel, S., Jaschinski, F., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0545-9 · Cited by 60
Jia, H., Wang, Z., Wang, Y., Liu, Y., Dai, H., Tong, C., Guo, Y., Guo, B., Ti, D., Han, X., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0741-6 · Cited by 60
Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy
Li, Q., & Xiang, M. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00776-4 · Cited by 59
Galot, R., Tourneau, C. L., Saâda-Bouzid, E., Daste, A., Even, C., Debruyne, P. R., Henry, S., Zanetta, S., Rutten, A., Licitra, L. F., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.003 · Cited by 58
NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development
Dezfouli, A. B., Yazdi, M., Pockley, A. G., Khosravi, M., Kobold, S., Wagner, E., & Multhoff, G. (2021) · Cells · doi:10.3390/cells10123390 · Cited by 58
Dumoulin, D. W., Visser, S., Cornelissen, R., van Gelder, T., Vansteenkiste, J., von der Thüsen, J. H., & Aerts, J. G. J. V. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.04.021 · Cited by 57
Hui, E. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201810035 · Cited by 56
Nakajima, M., Sakoda, Y., Adachi, K., Nagano, H., & Tamada, K. (2019) · Cancer Science · doi:10.1111/cas.14169 · Cited by 55
BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., Páyer, Á. R., González-García, E., López‐Soto, A., & Gonzalez, S. R. (2021) · Cancers · doi:10.3390/cancers13081766 · Cited by 54
Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma
Naumova, E. J., Mihaylova, A., Ivanova, M., & Mihailova, S. M. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0151-9 · Cited by 53
Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges
Wang, L., Dou, M., Ma, Q., Yao, R., & Liu, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105695 · Cited by 53
Soldevilla, M. M., Villanueva, H., Meraviglia-Crivelli, D., Menon, A. P., Ruiz, M., Cebollero, J., Villalba-Esparza, M., Moreno, B., Lozano, T., Llópiz, D., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.07.013 · Cited by 53
Yan, L., Qu, S., Shang, J., Shi, X., Kang, L., Xu, N., Zhu, M., Zhou, J., Jin, S. L., Yao, W., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3624 · Cited by 53
Regulation of PD-1 in T cells for cancer immunotherapy
Yu, X., Gao, R., Li, Y., & Zeng, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173240 · Cited by 52
Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
Sutherland, A. R., Owens, M. N., & Geyer, C. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197222 · Cited by 52
Yu, H., Chen, P., Cai, X., Chen, C., Zhang, X., He, L., Zhou, Y., Hong, S., & Zhang, B. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03017-z · Cited by 52
PD-1 /PD-L1 checkpoint in hematological malignancies
Annibali, O., Crescenzi, A., Tomarchio, V., Pagano, A., Bianchi, A., Grifoni, A., & Avvisati, G. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.01.014 · Cited by 51
Cobb, D. A., de Rossi, J., Liu, L., An, E., & Lee, D. W. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003816 · Cited by 51
Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines
Goyvaerts, C., & Breckpot, K. (2015) · Journal of Immunology Research · doi:10.1155/2015/785634 · Cited by 49
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner
Shi, L. Z., Goswami, S., Fu, T., Guan, B., Chen, J., Xiong, L., Zhang, J., Tang, D. N., Zhang, X., Vence, L. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0873 · Cited by 49
Hirashima, T., Kanai, T., Suzuki, H., Yoshida, H., MATSUSHITA, A., KAWASUMI, H., Samejima, Y., Noda, Y., Nasu, S., Tanaka, A., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13832 · Cited by 49
Suzuki, K., Yanagihara, T., Matsumoto, K., Kusaba, H., Yamauchi, T., Ikematsu, Y., Tanaka, K., Otsubo, K., Inoue, H., Yoneshima, Y., et al. (2020) · International Immunology · doi:10.1093/intimm/dxaa022 · Cited by 49
Okagawa, T., Konnai, S., Deringer, J. R., Ueti, M. W., Scoles, G. A., Murata, S., Ohashi, K., & Brown, W. C. (2016) · Infection and Immunity · doi:10.1128/iai.00278-16 · Cited by 47
Gravitz, L. (2013) · Nature · doi:10.1038/504s1a · Cited by 47
Şahin, İ. H., Goyal, S., Pumpalova, Y. S., Sonbol, M. B., Das, S., Haraldsdóttir, S., Ahn, D. H., Ciombor, K. K., Chen, Z., Draper, A., et al. (2021) · The Oncologist · doi:10.1002/onco.13741 · Cited by 46
Penter, L., Zhang, Y., Savell, A., Huang, T., Cieri, N., Thrash, E. M., Kim‐Schulze, S., Jhaveri, A., Fu, J., Ranasinghe, S., et al. (2021) · Blood · doi:10.1182/blood.2021010867 · Cited by 46
Immune Checkpoint Inhibitors-Induced Hepatitis
Tian, Y., Abu‐Sbeih, H., & Wang, Y. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_8 · Cited by 45
Current Clinical Trial Landscape of OX40 Agonists
Yadav, R., & Redmond, W. L. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01265-5 · Cited by 45
PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer
Sclafani, F. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30512-0 · Cited by 44
CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells
Gaber, T., Schönbeck, K., Hoff, H., Tran, C. L., Strehl, C., Lang, A., Ohrndorf, S., Pfeiffenberger, M., Röhner, E., Matziolis, G., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082312 · Cited by 44
PD-1 signaling pathway in sepsis: Does it have a future?
Chen, R., & Zhou, L. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108742 · Cited by 44
Shi, W. M., Yang, X., Xie, S., Zhong, D., Lin, X., Ding, Z., Duan, S., Mo, F., Liu, A., Yin, S., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.028 · Cited by 44
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer
Thompson, R. H., Allison, J. P., & Kwon, E. D. (2006) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2005.08.011 · Cited by 43
Differential PD-1/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer
Sobottka, B., Moch, H., & Varga, Z. (2021) · Breast Cancer Research · doi:10.1186/s13058-020-01380-w · Cited by 43
Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care
Qin, S. S., Melucci, A. D., Chacon, A. C., & Prieto, P. A. (2021) · Cells · doi:10.3390/cells10040808 · Cited by 43
Qin, M., Jin, Y., & Pan, L. (2021) · Oncology Letters · doi:10.3892/ol.2021.13097 · Cited by 43
Vossen, A. C. T. M., Tibbe, G. J. M., Kroos, M. J., van de Winkel, J. G. J., Benner, R., & Savelkoul, H. F. J. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250603 · Cited by 42
CTLA-4 Limits Anti-CD20–Mediated Tumor Regression
Ren, Z., Guo, J., Liao, J., Luan, Y., Liu, Z., Sun, Z., Liu, X., Liang, Y., Peng, H., & Fu, Y.-X. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0040 · Cited by 42
PD-1 Inhibitors in the Advanced Esophageal Cancer
Hong, Y., & Ding, Z. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01418 · Cited by 42
Zouein, J., Kesrouani, C., & Kourié, H. R. (2021) · Immunotherapy · doi:10.2217/imt-2020-0336 · Cited by 42
Bender, E. (2017) · Nature · doi:10.1038/d41586-017-08699-z · Cited by 42
Glial TIM-3 Modulates Immune Responses in the Brain Tumor Microenvironment
Kim, H.-S., Chang, C. Y., Yoon, H. J., Kim, K. S., Koh, H. S., Kim, S. S., Lee, S.-J., Kane, L., & Park, E. J. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2834 · Cited by 41
Bewersdorf, J. P., & Zeidan, A. M. (2021) · Cancers · doi:10.3390/cancers13071610 · Cited by 41
Liu, H., Xu, R., Gao, C., Zhu, T., Liu, L., Yang, Y., Zeng, H., Huang, Y., & Wang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.755668 · Cited by 41
CTLA-4 and CD28: similar proteins, neighbouring genes.
Balzano, C., Buonavista, N., Rouvier, É., & Golstein, P. (1992) · PubMed · Cited by 40
Lyu, Q., Lin, A., Cao, M., Xu, A., Luo, P., & Zhang, J. (2020) · Cancer Control · doi:10.1177/1073274820976665 · Cited by 40
Advancing oncolytic virus therapy by understanding the biology
Kaufman, H. L., & Maciorowski, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00490-4 · Cited by 40
Induction of T-cell memory by a dendritic cell vaccine: a computational model
Pappalardo, F., Pennisi, M. A., Ricupito, A., Topputo, F., & Bellone, M. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu059 · Cited by 39
Feld, E., & Mitchell, T. C. (2018) · Immunotherapy · doi:10.2217/imt-2017-0143 · Cited by 39
CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy
Ni, Y., Zhao, X., & Wang, W. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200623170738 · Cited by 39
Zhou, X., Wu, J., Duan, C., & Liu, Y. (2020) · Journal of Immunology Research · doi:10.1155/2020/7890985 · Cited by 39
Cited by
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H., & Kumar, S. (2024) · Biomedicines · doi:10.3390/biomedicines12010201 · Cited by 390
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Metadata
- Authors
- Wang, D.-R., Wu, X.-L., & Sun, Y.-L.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2022-09-19
- Volume
- 7
- Issue
- 1
- Pages
- 331-331
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4296373959
- Cited by
- 501
- References
- 486
- FWCI
- 37.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.